Online Medical Reference

Myelodysplastic Syndromes

Mikkael A. Sekeres

Michael Keng

Published: April 2014

Definition

Historically, the myelodysplastic syndromes (MDS) have been referred to as oligoblastic leukemia, refractory anemia, smoldering acute leukemia, or preleukemia. They represent a group of heterogeneous hematopoietic disorders derived from an abnormal multipotent progenitor cell, characterized by ineffective hematopoiesis, bone marrow failure, peripheral blood cytopenias, and reduced survival. MDS may be classified as indolent or aggressive (lower- or higher-risk), depending on life expectancy and likelihood of progression to acute myeloid leukemia (AML).

Back to Top

Prevalence and Risk Factors

The precise incidence rate of MDS in the United States is still evolving. This may be in part due to the difficulty of defining MDS in the setting of changing classification systems. However, most studies report that MDS affects between 12,000 and 20,000 people in the United States each year. Surveillance, Epidemiology and End Results (SEER) and North American Association of Central Cancer Registries, Inc. (NAACCR) data report an incidence rate of 4.5 per 100,000 people in 2006. In general, MDS is a disease of older adults, with a median age at diagnosis of approximately 71 years with a male predominance. With the exception of treatment-induced MDS (MDS that develops following chemotherapy or radiation treatment for another cancer), age of onset prior to 50 is uncommon.

Risk factors for developing MDS include the following:

  • Age: Population studies in England have found that the crude yearly incidence rate increases from 0.5 per 100,000 people younger than 50 years to 89 per 100,000 people older than 80 years.
  • Genetic predisposition: Familial syndromes have been reported but are rare. Congenital syndromes that put a patient at risk for MDS include Down's syndrome, Fanconi Anemia, Dyskeratosis Congentia, Schwachman Diamond, and neurofibromatosis.
  • Environmental exposure: This includes particularly benzene and possibly other industrial solvents.
  • Prior therapy, including radiation treatment, alkylating agents (e.g., chlorambucil, cyclophosphamide, melphalan), and other chemotherapy agents.

For alkylating agents, the risk of developing a secondary MDS or AML starts with the end of therapy and peaks at four years, with a plateau at ten years.

Back to Top

Pathophysiology and Natural History

In MDS, the hematopoietic stem cells that define the disease are clonally derived. Generally, MDS can be divided into two major subtypes–indolent (or lower-risk) MDS, in which pro-apoptotic, pro-inflammatory, and bone marrow microenvironment forces predominate, and aggressive (or higher-risk) MDS, in which proproliferative factors are more common. In indolent MDS, inhibitory cytokines, including tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), transforming growth factor-β (TGF-β), and Fas ligand promote apoptosis. As genetic lesions accumulate, indolent MDS becomes proliferative MDS and eventually AML. This occurs as oncogenes are activated and tumor suppressor genes are inactivated. In the proliferative categories, ras, FMS, and p53 mutations are more common than inhibitory cytokines, and are believed to facilitate the transformation to AML. In general, bone marrow stem cells in MDS are less responsive to and produce fewer hematopoietic growth factors, including IL-3, IL-6, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor. Peripheral blood cytopenias result from this process. Thus, there is the paradox of having a hypercellular bone marrow in patients requiring blood transfusions.

Cytogenetic abnormalities are found in approximately 50% of MDS patients using conventional karyotyping techniques, and in up to 80% using single nucleotide polymorphism array technology. Typically, trisomy 8 and monosomy 5 or 7 will be present. Findings of these abnormalities in patients with frank AML indicate probable evolution (which may be subclinical) from an antecedent MDS, which confers a worse prognosis. Therapy-related MDS can be associated with these same abnormalities in addition to translocations or rearrangements involving 11q23 or 21q22. Favorable abnormalities include del(5q), del(20q), -Y, or normal cytogenetics, whereas unfavorable abnormalities are found with complex cytogenetics (three or more cytogenetic abnormalities) or chromosome 7 abnormalities.

Deficiencies in hematopoiesis lead to cytopenias, which may be severe. Not surprisingly, morbidity and mortality result from anemia, bleeding, and infection, along with transformation to AML, which occurs in approximately one-third of patients.

Back to Top

Signs and Symptoms

Recognition of this entity has increased over the past decade, and should be suspected in older adults with anemia, thrombocytopenia, leukopenia, or a combination of these abnormalities. MDS often manifests as a refractory cytopenia in an older adult who may be entirely asymptomatic. A macrocytic or normocytic anemia is found in almost all MDS patients, and frequently is accompanied by thrombocytopenia, leukopenia, or both. Typical symptoms reflect underlying cytopenias—patients with anemia frequently complain of fatigue, shortness of breath, loss of appetite, and even exacerbation of underlying cardiac symptoms; patients with thrombocytopenia may have spontaneous bruising, the appearance of petechiae (particularly in dependent areas, such as the shins, or in areas exposed to minor trauma, such as skin under elastic waistbands), or bleeding of mucosal surfaces (including the gums when brushing teeth); and patients with leukopenia may have recurrent infections, particularly of the skin, mucosal surfaces (especially the oral and rectal mucosa), and lungs.

MDS can be associated with paraneoplastic syndromes related to autoimmune processes, particularly when MDS overlaps with myeloproliferative neoplasms (such as chronic myelomonocytic leukemia, often associated with splenomegaly). These may be dermatologic (e.g., psoriasis or Sweet's syndrome), rheumatologic (e.g., vasculitis), hematologic (e.g., hemolytic anemia or Glanzmann's disease [an acquired glycoprotein IIB/IIIA inhibition resulting in abnormal platelet function]), or endocrinologic (e.g., hypothyroidism, diabetes insipidus). Cytokine release (see earlier, "Pathophysiology and Natural History") may result in constitutional symptoms, such as anorexia, weight loss, and even low-grade fevers. Splenomegaly, seen in overlap disorders, may be associated with left upper quadrant pain.

Back to Top

Diagnosis

MDS is diagnosed through a combination of abnormal findings in the peripheral blood and bone marrow. Morphologic abnormalities should be present in at least 10% of cells in a given lineage. In the peripheral blood, erythrocytes may be macrocytic, nucleated, or stippled, whereas neutrophils may be hyposegmented, hypogranular, or bilobed, with chromatin condensation (pseudo Pelger-Huët cells). In the bone marrow, erythrocyte precursors may have megaloblastoid changes, contain ringed sideroblasts, or include Howell-Jolly bodies. Myeloid maturation may be stunted, and megakaryocytes can be dysplastic.

Subtypes of MDS are defined using one of two classification systems. The French-American-British (FAB) system has been used widely since 1982 and is useful in predicting rates of survival and transformation to AML (Table 1). In the FAB system, MDS is divided into refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia, now considered an overlap syndrome that can include features of a myelodysplastic syndrome, myeloproliferative neoplasm, or both.

Table 1: French-American-British (FAB) Myelodysplastic Syndrome (MDS) Classification System
MDS Subtype Peripheral Blasts (%) Bone Marrow Blasts (%) AML Transformation Median Survival (months) MDS Diagnoses (%)
Refractory anemia (RA) ≤1 <5 10-20 30-65 10-40
Refractory anemia with ringed sideroblasts (RARS) ≤1 <5 10-35 34-83 10-35
Refractory anemia with excess blasts (RAEB) <5 5-20 >50 8-18 25-30
Refractory anemia with excess blasts in transformation (RAEB-T) ≥5 21-29 60-100 4-11 10-30
Chronic myelomonocytic leukemia (CMML) <5 ≤20 >40 15-32 10-20

AML, acute myelogenous leukemia.

Data from Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189–199.

In 1999, the World Health Organization (WHO) published its classification of hematopoietic and lymphoid neoplasms, and in 2002 published a clarification and rationale for differences between the FAB and WHO classifications (Table 2). The most important difference was the lowering of the blast threshold for the diagnosis of AML, from 30% to 20% blasts in the blood or bone marrow. Chronic myelomonocytic leukemia was also formally separated from the myelodysplastic syndromes, and a cytogenetically defined MDS subgroup, patients with an isolated del(5q) abnormality—which confers a good prognosis, is associated with normal or elevated platelet counts, and is found in 5% to 13% of patients—was identified. The WHO system was revised again in 2009, the most important changes being the recognition of patients with refractory cytopenia with unilineage dysplasia (which included refractory anemia, neutropenia, or thrombocytopenia) and refractory cytopenia with multilineage dysplasia (in which two or more cell lines are involved).

Table 2: World Health Organization Myelodysplastic Syndrome Classification and Criteria
MDS Subtype Blood Findings Bone Marrow Findings
Refractory cytopenia with unilineage dysplasia (RCUD): refractory anemia (RA), refractory neutropenia (RN), refractory thrombocytopenia (RT) Unicytopenia or bicytopenia*
No or rare blasts (<1%)†
Unilineage dysplasia: ≥10% of the cells in one myeloid lineage
<5% blasts
<15% of erythroid precursors are ring sideroblasts
Refractory anemia with ring sideroblasts (RARS) Anemia
No blasts
≥15% of erythroid precursors are ring sideroblasts
Erythroid dysplasia only
<5% blasts
Refractory cytopenia with multilineage dysplasia (RCMD) Cytopenia(s)
No or rare blasts (<1%)†
No Auer rods
<1 x 109/L monocytes
Dysplasia in ≥10% of the cells in ≥2 myeloid lineage (neutrophil and/or erythroid precursors and/or megakaryocytes)
<5% blasts in marrow
No Auer rods
±15% ring sideroblasts
Refractory anemia with excess blasts-1 (RAEB-1) Cytopenia(s)
<5% blasts†
No Auer rods
<1 x 109/L monocytes
Unilineage or multilineage dysplasia
5% to 9% blasts†
No Auer rods
Refractory anemia with excess blasts-2 (RAEB-2) Cytopenia(s)
5% to 19% blasts‡
±Auer rods‡
<1 x 109/L monocytes
Unilineage or multilineage dysplasia
10% to 19% blasts‡
±Auer rods‡
Myelodysplastic syndrome - unclassified (MDS-U) Cytopenias
<1% Blasts†
Unequivocal dysplasia in <10% of cells in one or more myeloid lineage when accompanied by a cytogenetic abnormality considered as presumptive evidence for a diagnosis of MDS
<5% blasts
MDS associated with isolated del(5q) Anemia
Usually normal or increased platelet count
No or rare blasts (<1%)
Normal to increased megakaryocytes with hypolobated nuclei
<5% blasts
Isolated del(5q) cytogenetic abnormality
No Auer rods

MDS, myelodysplastic syndrome.

* Bicytopenia may occasionally be observed. Cases with pancytopenia should be classified as MDS-U.

† If the marrow myeloblast percentage is <5% but there are 2% to 4% myeloblasts in the blood, the diagnostic classification is RAEB-1. Cases of RCUD and RCMD with 1% myeloblasts in the blood should be classified as MDS-U.

‡ Cases with Auer rods and <5% myeloblasts in the blood and <10% in the marrow should be classified as RAEB-2. Although the finding of 5% to 19% blasts in the blood is, in itself, diagnostic of RAEB-2, cases of RAEB-2 may have <5% blasts in the blood if they have Auer rods or 10% to 19% blasts in the marrow or both. Similarly, cases of RAEB-2 may have <10% blasts in the marrow but may be diagnosed by the other two findings, Auer rod + and/or 5% to 19% blasts in the blood.

Republished with permission of The American Society of Hematology (Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization [WHO] classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937–951); permission conveyed through Copyright Clearance Center, Inc.

A differential diagnosis includes the following:

  • Anemia from other causes, such as vitamin deficiencies, iron deficiency from an inadequate diet or blood loss, endocrine disorders, infections, another cancer with bone marrow involvement, rheumatologic disorders, or medication effect.
  • Thrombocytopenia resulting from idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, or medication effect.
  • Leukopenia from other causes, such as infections (e.g., human immunodeficiency virus), hepatitis, or parvovirus), rheumatologic disorders, or medication effect.

If MDS is suspected, a bone marrow biopsy and aspirate should be performed. The diagnosis is made based on cell morphology, immunohistochemistry, and, in the case of more advanced subtypes of MDS, flow cytometry. Obtaining a bone marrow aspirate sample for cytogenetics is crucial, because abnormalities may help in establishing the diagnosis and in risk stratification (Tables 3, 4, 5, and 6).

Table 3: Myelodysplastic Syndrome International Prognostic Scoring System
  Score

Prognostic variable 0 0.5 1.0 1.5 2.0
Bone marrow blasts (%) <5 5 - 10   11 - 20 21 - 30
Cytogenetics Good Intermediate Poor
Cytopenias 0/1 2/3

Republished with permission of The American Society of Hematology (Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079–2088); permission conveyed through Copyright Clearance Center, Inc.


Table 4: Myelodysplastic Syndrome – Cytogenetic Prognosis from the Revised International Prognostic Scoring System
Prognostic Subgroup Abnormality Median Survival (months) Median AML Transformation (months)
Very good del(11q), -Y 60.8 NR
Good normal, del(20q), del(5q) alone and double, del(12p) 48.6 NR
Intermediate del(7q), +8, i(17q), +19, any other single or double 26.0 78.0
Poor inv(3)/t(3q)/del(3q), -7, double including 7q-, complex (3 abnormalities) 15.8 21.0
Very poor complex (>3 abnormalities) 5.9 8.2

AML, acute myeloid leukemia; NR, not reached.

Data from Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30:820–829.


Table 5: Myelodysplastic Syndrome - Revised International Prognostic Scoring System
  Score

Prognostic variable 0 0.5 1.0 1.5 2.0 3.0 4.0
Cytogenetics Very good   Good   Intermediate Poor Very poor
Bone marrow blasts (%) ≤2   >2 - <5   5 - 10 >10  
Hemoglobin ≥10   8 - <10 <8
Platelets ≥100 50 - <100 <50
Absolute neutrophil count ≥0.8 <0.8  

Republished with permission of The American Society of Hematology (Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454–2465); permission conveyed through Copyright Clearance Center, Inc.


Table 6: Myelodysplastic Syndrome Prognosis - Revised International Prognostic Scoring System
Risk Score IPSS-R Subgroup Patients (%) 7,012 Total Survival, All (years) Hazard Ratio [95% CI] Patients (%) 6,485 Total AML/25% (years) Hazard Ratio [95% CI]
≤1.5 Very low 19% 8.8 (7.8-9.9) 0.5 (0.46-0.59) 19% NR (14.5-NR) 0.5 (0.4-0.6)
>1.5 - 3 Low 38% 5.3 (5.1-5.7) 1.0 (0.93-1.1) 37% 10.8 (9.2-NR) 1.0 (0.86-1.2)
>3 - 4.5 Intermediate 20% 3.0 (2.7-3.3) 2.0 (1.8-2.1) 20% 3.2 (2.8-4.4) 3.0 (2.7-3.5)
>4.5 - 6 High 13% 1.6 (1.5-1.7) 3.2 (2.9-3.5) 13% 1.4 (1.1-1.7) 6.2 (5.4-7.2)
>6 Very high 10% 0.76 (0.7-0.8) 8.0 (7.2-8.8) 11% 0.73 (0.7-0.9) 12.7 (10.6-15.2)

IPSS-R, Revised International Prognostic Scoring System; NR, not reached.

IPSS-R, Revised International Prognostic Scoring System; NR, not reached. Republished with permission of The American Society of Hematology (Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454–2465); permission conveyed through Copyright Clearance Center, Inc.

Other laboratory tests that should be obtained to narrow the differential diagnosis include vitamin B12, folate, and iron studies, including a ferritin level, serum erythropoietin level determination, certain rheumatologic studies (including antinuclear antibody or rheumatoid factor assay in select patients), or monitoring for infectious causes, including human immunodeficiency virus and hepatitis serologies. Although not specific, determination of the erythrocyte sedimentation rate and lactate dehydrogenase level can establish the presence of an acute process or rapid cell turnover.

Summary

  • MDS can be classified into 5 or 10 subtypes, depending on the system (FAB or WHO) used. In general, MDS is indolent (lower-risk) or proliferative (higher-risk).
  • In patients with cytopenias, rule out vitamin or iron deficiencies, rheumatologic, or infectious causes.
  • Obtain a bone marrow biopsy and aspirate. Always carry out cytogenetic testing on the aspirate.

Back to Top

Treatment

MDS is a heterogeneous disease, with varied options for the treatment. These range from supportive care, which includes blood product transfusions and the use of growth factors, to intensive therapy with allogeneic hematopoietic stem cell transplantation (HSCT). Treatment selection should be based on the patient's age, performance status, and Myelodysplastic Syndrome International Prognostic Scoring System (IPSS) and Revised International Prognostic Scoring System (IPSS-R) subgroup classification. The main goal of MDS therapy is to provide symptom control and to improve quality of life for lower-risk subtypes, and to extend survival and delay transformation to AML in higher-risk groups. Treatment is indicated for lower-risk MDS if there is symptomatic anemia, thrombocytopenia, or recurrent infections in the setting of neutropenia, and for higher-risk MDS under most circumstances regardless of blood counts or symptoms. At this time, there is no evidence that treatment of asymptomatic patients improves overall survival. Additionally, the only curative option for MDS is allogeneic HSCT.

Patients with lower-risk MDS, without excess myeloblasts, who may be dependent on blood product transfusions, may derive some benefit from the use of growth factors. Often, recombinant human erythropoietin (epoetin alfa [EPO, Procrit, Epogen], at doses of 60,000 to 80,000 U weekly) or darbepoietin (Aranesp, at a dose of 500 mcg every 2 to 3 weeks) is used initially as a single agent, in escalating doses. Either increases hemoglobin levels and/or decreases transfusion needs in approximately 40% of lower-risk patients. Growth factor agents tend to be more effective in lower-risk MDS patients with lower serum erythropoietin levels, less than 500 U/L, who do not already require frequent blood transfusions (defined as less than 2 units packed red blood cells per month).

In patients who are transfusion dependent, or who are unlikely to respond to growth factors, disease-modifying therapy may be initiated. Less intensive (midrange) therapeutic options for patients with lower-risk MDS include the use of lenalidomide (Revlimid) or immunosuppressive therapy. Lenalidomide, a derivative of thalidomide, purportedly works through inhibition of halpodeficient phosphatase activity in the common deleted region that plays a key role in cell cycle regulation, and through a defect in the ribosomal protein function. It has been investigated in two large phase II trials and in one phase III study in patients with a del(5q) cytogenetic abnormality and in patients with non-del(5q) lower-risk MDS. Response rates, defined as transfusion independence, in patients with the del(5q) abnormality are approximately two-thirds, with 44% of patients attaining a cytogenetic remission. In patients with lower-risk MDS who lack the del(5q) abnormality, the transfusion independence response rate is lower, approximately 25%. Lenalidomide has been approved by the U.S. Food and Drug Administration (FDA) for use in transfusion-dependent patients with early MDS who have the del(5q) abnormality.

Immunosuppressive therapy (which includes the use of antithymocyte globulin [ATG, Atgam] and cyclosporine A [Neoral, Sandimmune]) takes advantage of the immune-mediated aspects of MDS and may be effective in the subset of patients with MDS that resembles aplastic anemia, with a hypocellular bone marrow, or in those with other autoimmune stigmata. Improved hematologic counts and transfusion independence may be achieved in up to 30% to 40% of appropriately selected patients.

For patients with higher-risk MDS, two drugs approved for use in MDS by the FDA deserve mention, azacitidine (5-AZA, Vidaza), and decitabine (Dacogen). These hypomethylating agents purportedly work by reactivating tumor suppressor genes and through direct cytotoxic mechanisms, and may induce hematopoietic progenitor cell differentiation. In a recent phase III trial in higher-risk patients, responses occurred in approximately 50% of patients, and survival was doubled at 2 years of follow-up in patients receiving azacitidine, compared to those treated with conventional care, including best supportive care or chemotherapy. Decitabine has been investigated in a multicenter phase III study, in which responses were achieved in 30% of patients, with a complete and partial remission rate in 17%, though no overall survival advantage has been demonstrated compared to best supportive care.

Allogeneic HSCT, the only potentially curative approach to MDS, is a realistic option for only about 5% to 10% of patients, due to advanced patient age at time of MDS diagnosis, co-morbidities, advanced age of potential sibling donors, and patient preference. Conditioning regimens typically consist of busulfan (Myleran) and cyclophosphamide (Cytoxan) or fludarabine, and long-term (often 2-year) disease-free survival approaches 40%, although studies using fully myeloablative regimens have often included younger MDS patients (with a median age between 30 and 45 years). Treatment-related mortality may be as high as 40% to 50%. Newer approaches take advantage of nonmyeloablative ("mini") conditioning regimens in an effort to reduce treatment-related mortality and to include older patients with MDS. This type of transplantation can be offered to patients up to 70 years of age who otherwise are in good health. Allogeneic HSCT should be considered as up-front therapy in patients with higher-risk subtypes of MDS, but can be delayed in patients with lower-risk MDS.

Back to Top

Summary

  • Determine whether the patient has lower- or higher-risk MDS.
  • For lower-risk MDS, growth factors such as erythropoiesis stimulating agents may be initiated once patients start to require blood transfusions.
  • Once growth factors fail, or in patients less likely to respond to growth factors, disease-modifying approaches lead to responses in 15% to 65% of patients.
  • For higher-risk MDS, allogeneic HSCT or therapy with hypomethylating agents should be initiated immediately.

Back to Top

Outcomes

The most widely used prognostic classification system for MDS is the IPSS (Tables 3 and 7). The first IPSS was derived from a study published in 1997. This study was based on survival data of 816 patients with primary MDS based upon the FAB classification system and treated in general with supportive care only. The IPSS separates patients into four distinct subgroups based solely on the percentage of bone marrow blasts, cytogenetics, and the number of cytopenias. Due to several limitations of the first IPSS, new cytogenetic categories were developed for a revised IPSS (IPSS-R) in 2012. The IPSS-R was based on data from over 7,000 patients with primary MDS diagnosed using the FAB or WHO classifications and validated in an independent cohort. The IPSS-R changes include: a larger number of cytogenetic abnormalities which are given more weight than previously, different cut-offs for blast percentage, and sensitivity to degrees of cytopenias. Patients with fewer bone marrow blasts and cytopenias and with better cytogenetic profiles (Y-, del(11q), normal, del(5q), del(20q), del(12p)) have a prolonged median survival, whereas those with more blasts and cytopenias and complex cytogenetic profiles have a shorter survival.

Table 7: Myelodysplastic Syndrome Prognosis
Score IPSS Subgroup Median Survival (years)
0 Low 5.7
0.5-1.0 Intermediate 1 3.5
1.5-2.0 Intermediate 2 1.2
>2.5 High 0.4

IPSS, International Prognostic Scoring System.

Data from Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079–2088.

Back to Top

Suggested Readings

  • Allampallam K, Shetty V, Mundle S, et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 2002; 75:289–297.
  • Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992; 82:358–367.
  • Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189–199.
  • Catenacci DV, Schiller GJ. Myelodysplastic syndromes: a comprehensive review. Blood Rev 2005; 19:301–319.
  • Fenaux P, Giagounidis A, Selleslag D, et al; for MDS-004 Lenalidomide del5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q [published online ahead of print July 13, 2011]. Blood 2011; 118:3765–3776.
  • Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndromes. Semin Hematol 1996; 33:127–138.
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; for the International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study [published online ahead of print February 21, 2009]. Lancet Oncol 2009; 10:223–232.
  • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079–2088.
  • Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454–2465.
  • Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106:1794–1803.
  • Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328:593–602.
  • List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352:549–557.
  • Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group [published online ahead of print April 11, 2011]. J Clin Oncol 2011; 29:1987–1996.
  • Melchert M, Kale V, List A. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opinion Hematol 2007; 14:123–129.
  • Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99:699–705.
  • Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996; 87:4076–4081.
  • Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998; 83:358–368.
  • Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge [published online ahead of print February 13, 2012]. J Clin Oncol 2012; 30:820–829.
  • Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20:2429–2440.
  • Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes [published online ahead of print April 8, 2009]. Blood 2009; 114:937–951.
  • Wijermans P, Lübbert M, Verhoef G, et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000; 18:956–962.

Back to Top